Supplementary Material for: Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary

Dataset

Bibliographical metadata

Description

<b><i>Purpose:</i></b> The RADIANT-4 randomized phase 3 study
demonstrated significant prolongation of median progression-free
survival (PFS) with everolimus compared to placebo (11.0 [95% CI
9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced,
progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine
tumors (NET). This analysis specifically evaluated NET patients with GI
and unknown primary origin. <b><i>Methods:</i></b> Patients in the
RADIANT-4 trial were randomized 2:1 to everolimus 10 mg/day or placebo.
The effect of everolimus on PFS was evaluated in patients with NET of
the GI tract or unknown primary site. <b><i>Results:</i></b> Of the 302
patients enrolled, 175 had GI NET (everolimus, 118; placebo, 57) and 36
had unknown primary (everolimus, 23; placebo, 13). In the GI subset, the
median PFS by central review was 13.1 months (95% CI 9.2-17.3) in the
everolimus arm versus 5.4 months (95% CI 3.6-9.3) in the placebo arm;
the hazard ratio (HR) was 0.56 (95% CI 0.37-0.84). In the unknown
primary patients, the median PFS was 13.6 months (95% CI 4.1-not
evaluable) for everolimus versus 7.5 months (95% CI 1.9-18.5) for
placebo; the HR was 0.60 (95% CI 0.24-1.51). Everolimus efficacy was
also demonstrated in both midgut and non-midgut populations; a 40-46%
reduction in the risk of progression or death was reported for patients
in the combined GI and unknown primary subgroup. Everolimus had a
benefit regardless of prior somatostatin analog therapy. <b><i>Conclusions:</i></b>
Everolimus showed a clinically meaningful PFS benefit in patients with
advanced progressive nonfunctional NET of GI and unknown primary,
consistent with the overall RADIANT-4 results, providing an effective
new standard treatment option in this patient population and filling an
unmet treatment need for these patients.
Date made available18 Jul 2017
Publisherfigshare

Related information

Publications

Research output: Contribution to journalArticlepeer-review

View all (1)